Trials / Completed
CompletedNCT03075241
Z-Drugs for Sleep Disorders in Alzheimer's Disease
Z-Drugs for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Triple-blind, Placebo-controlled Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Brasilia University Hospital · Academic / Other
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Zolpidem and Zoplicone are efective in the treatment of sleep disorders in Alzheimer's disease (AD)
Detailed description
Sleep disorders (SD) affects 35 to 50 percent of patients with AD. These disorders often make caring for patients at home very difficult. Zolpidem and Zoplicone are prescribed drugs for sleep disorder in AD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zolpidem | Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights |
| DRUG | Zoplicone | Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights |
| DRUG | Placebo | Inactive or inert pill which will be used as a comparator |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2020-04-01
- Completion
- 2020-04-01
- First posted
- 2017-03-09
- Last updated
- 2020-11-10
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT03075241. Inclusion in this directory is not an endorsement.